Literature DB >> 28059849

Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study.

Jiannan Dai1, Jingbo Hou, Lei Xing, Haibo Jia, Sining Hu, Tsunenari Soeda, Yoshiyasu Minami, Daniel Ong, Rocco Vergallo, Shaosong Zhang, Hang Lee, Bo Yu, Ik-Kyung Jang.   

Abstract

OBJECTIVE: Age-related structural and functional changes in vessel wall may affect the time course of vascular response to statin therapy. In this study, we sought to compare the response of lipid-rich plaque to statin therapy in elderly versus younger patients using optical coherence tomography and intravascular ultrasound. PATIENTS AND METHODS: Sixty-nine patients who underwent serial optical coherence tomography and intravascular ultrasound at the time point of baseline, 6, and 12 months were divided into two groups according to median age: group A (age<57 years, n=35) and group B (age≥57 years, n=34). Patients were treated with intensive (atorvastatin 60 mg/day) or moderate (atorvastatin 20 mg/day or rosuvastatin 10 mg/day) statin therapy.
RESULTS: A continuous increase in fibrous-cap thickness (FCT) from baseline to 12 months was observed in both groups (P<0.001, <0.001, respectively). Intensive statin induced greater percent change in FCT at 12 months than moderate statin in group B (P=0.020), but not in group A (P=0.251). Mean lipid arc decreased significantly at 12 months in two groups (P<0.001, <0.001, respectively), and this response was delayed for 6 months (P=0.403) and began to decrease during the second 6 months (P<0.001) in group B. Normalized total atheroma volume decreased significantly in group A (P<0.001), but not in group B (P=0.349).
CONCLUSION: Statin therapy could stabilize lipid-rich plaque irrespective of age, and intensive statin therapy was more effective than a moderate dose of statin in increasing FCT, particularly in older patients. A delayed response of lipid content and unfavorable change in normalized total atheroma volume to statin were observed in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28059849     DOI: 10.1097/MCA.0000000000000465

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  2 in total

1.  Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.

Authors:  Stephen J Nicholls; Steven E Nissen; Francesco Prati; Stephan Windecker; Yu Kataoka; Rishi Puri; Thomas Hucko; Helina Kassahun; Jason Liao; Ransi Somaratne; Julie Butters; Giuseppe Di Giovanni; Stephen Jones; Peter J Psaltis
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

Review 2.  Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging.

Authors:  Giuseppe Di Giovanni; Stephen J Nicholls
Journal:  Am J Prev Cardiol       Date:  2022-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.